Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metast...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-10-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025229210877952 |
|---|---|
| author | D. A. Enaldieva P. V. Krivorotko E. N. Imyanitov E. K. Zhiltsova R. V. Donskikh L. F. Shaikhelislamova L. P. Gigolaeva V. F. Semiglazov |
| author_facet | D. A. Enaldieva P. V. Krivorotko E. N. Imyanitov E. K. Zhiltsova R. V. Donskikh L. F. Shaikhelislamova L. P. Gigolaeva V. F. Semiglazov |
| author_sort | D. A. Enaldieva |
| collection | DOAJ |
| description | BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metastatic BRCA-associated TNBC. Neoadjuvant regimens based on the use of anthracyclines and taxanes are the standard of drug therapy for primary BRCA-associated breast cancer. At present, there are few data regarding the addition of platinum drugs to anthracycline-taxane neoadjuvant chemotherapy in the treatment of primary BRCA-associated TNBC. This review details the various treatment options for both primary and metastatic BRCA-associated TNBC. It has been shown that the development of new strategies for the neoadjuvant chemotherapy of patients with primary BRCA-associated TNBC is an urgent clinical need to reduce the risks of recurrence and progression. |
| format | Article |
| id | doaj-art-c0e113ef1add4fcf8c95f52edf7214f0 |
| institution | DOAJ |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| publishDate | 2023-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj-art-c0e113ef1add4fcf8c95f52edf7214f02025-08-20T03:00:54ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872023-10-0110381410.17650/2313-805X-2023-10-3-8-14289Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancerD. A. Enaldieva0P. V. Krivorotko1E. N. Imyanitov2E. K. Zhiltsova3R. V. Donskikh4L. F. Shaikhelislamova5L. P. Gigolaeva6V. F. Semiglazov7N. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaN. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of RussiaBRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metastatic BRCA-associated TNBC. Neoadjuvant regimens based on the use of anthracyclines and taxanes are the standard of drug therapy for primary BRCA-associated breast cancer. At present, there are few data regarding the addition of platinum drugs to anthracycline-taxane neoadjuvant chemotherapy in the treatment of primary BRCA-associated TNBC. This review details the various treatment options for both primary and metastatic BRCA-associated TNBC. It has been shown that the development of new strategies for the neoadjuvant chemotherapy of patients with primary BRCA-associated TNBC is an urgent clinical need to reduce the risks of recurrence and progression.https://umo.abvpress.ru/jour/article/view/564<i>brca1/2</i> mutationsneoadjuvant chemotherapypathological complete responsetriple-negative breast cancermetastatic breast cance |
| spellingShingle | D. A. Enaldieva P. V. Krivorotko E. N. Imyanitov E. K. Zhiltsova R. V. Donskikh L. F. Shaikhelislamova L. P. Gigolaeva V. F. Semiglazov Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer Успехи молекулярной онкологии <i>brca1/2</i> mutations neoadjuvant chemotherapy pathological complete response triple-negative breast cancer metastatic breast cance |
| title | Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer |
| title_full | Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer |
| title_fullStr | Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer |
| title_full_unstemmed | Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer |
| title_short | Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer |
| title_sort | current approaches to systemic treatment of i brca i associated triple negative breast cancer |
| topic | <i>brca1/2</i> mutations neoadjuvant chemotherapy pathological complete response triple-negative breast cancer metastatic breast cance |
| url | https://umo.abvpress.ru/jour/article/view/564 |
| work_keys_str_mv | AT daenaldieva currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT pvkrivorotko currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT enimyanitov currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT ekzhiltsova currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT rvdonskikh currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT lfshaikhelislamova currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT lpgigolaeva currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer AT vfsemiglazov currentapproachestosystemictreatmentofibrcaiassociatedtriplenegativebreastcancer |